Pietro Di Marino - Concepedia

Author

Pietro Di Marino

University of Chieti-Pescara ORCID

Also Known As

Di Marino, P, Michele DE TURSI, P Marino, P. Di Marino, P. Marino, Pietro Di Marino, Pietro Marino

212

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

University of Chieti-Pescara Ospedale SS. Annunziata San Salvatore Hospital University of L'Aquila Università Campus Bio-Medico

About

Pietro Di Marino is an author at University of Chieti-Pescara specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	588
2	Immunology	8	8	545
3	Health Sciences	1	1	29
4	Hepatology	1	1	22
5	Microbiology	1	1	22

Pietro Di Marino

Publications

Citations

H-Index

Page 1

	Year	Citations
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, Journal for ImmunoTherapy of Cancer	2019	400
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients Alessio Cortellini, Rita Chiari, Biagio Ricciuti, Clinical Lung Cancer Cancer ImmunosurveillanceAnti-pd1 ImmunotherapyImmunodeficienciesImmunologyClinical Trials	2019	174
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients Vincenzo Graziano, Antonino Grassadonia, Laura Iezzi, The Breast	2019	170
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy Alessio Cortellini, Massimo Di Maïo, Olga Nigro, Journal for ImmunoTherapy of Cancer	2021	132
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, European Journal of Cancer Advanced CancerMedicineImmune Checkpoint InhibitorsImmunologyPathology	2020	111
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation Alessio Cortellini, Biagio Ricciuti, Marcello Tiseo, Journal for ImmunoTherapy of Cancer	2020	95
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study Alessio Cortellini, Federico Bozzetti, Pierpaolo Palumbo, Scientific Reports	2020	87
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna, Clinical Lung Cancer Pd-l1 ExpressionClinical EpidemiologyImmunologyImmune Checkpoint InhibitorClinical Outcomes	2020	82
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer Alessio Cortellini, Antonio D’Alessio, Siobhan Cleary, Clinical Cancer Research	2023	67
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario Luca Cantini, Giulia Mentrasti, Gian Luigi Russo, ESMO Open	2022	62

Page 1